NR 546 Final Exam Prep Document | 2026/2027 Edition | 150
Verified Questions - 129 Questions with Answers
NR 546 Final Exam 2026-129 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation resource for NR 546, Advanced Psychopharmacology, offers
150 meticulously verified questions and answers, all graded A+. Designed for the 2026/2027 academic
year, it aligns with the latest guidelines and evidence-based practices. Each question is accompanied by
detailed rationales to reinforce understanding and ensure exam readiness. This document is an essential
tool for nursing students aiming to excel in their final examination.
Key Features:
Foundations of Psychopharmacology: Neurotransmission, receptor pharmacology, and pharmacokinetics
Antidepressants: SSRIs, SNRIs, TCAs, MAOIs, and atypical antidepressants
Antipsychotics: First-generation (typical) and second-generation (atypical) agents
Mood Stabilizers: Lithium, valproate, lamotrigine, and other anticonvulsants
Anxiolytics and Sedative-Hypnotics: Benzodiazepines, buspirone, and non-benzodiazepine hypnotics
Stimulants and Non-Stimulants for ADHD: Methylphenidate, amphetamines, atomoxetine, and alpha-2
agonists
Cognitive Enhancers: Donepezil, rivastigmine, galantamine, and memantine for dementia
Substance Use Disorder Pharmacotherapy: Nicotine, alcohol, opioid, and other substance use treatments
Special Populations: Pediatric, geriatric, pregnancy, and lactation considerations
Psychopharmacology in Medical Conditions: Drug interactions, contraindications, and monitoring
Patient Education and Adherence: Strategies for improving medication adherence and patient counseling
Legal and Ethical Considerations: Prescriptive authority, informed consent, and controlled substance
regulations
Evidence-Based Practice: Clinical guidelines, algorithms, and outcome measures
Case-Based Application: Integrating psychopharmacology into clinical scenarios
Recent Advances: New drugs, research findings, and updates in the field
Exam Strategies: Test-taking tips and common pitfalls
Updates for 2026:
- Updated to reflect the latest FDA approvals and warnings in psychopharmacology
- Revised to align with 2026-2027 clinical practice guidelines from APA and other organizations
- Enhanced rationales to include evidence-based research and clinical pearls
- Expanded coverage of telepsychiatry and digital health considerations in medication management
- Incorporated new safety alerts and drug interaction data
Abstract:
This exam preparation document for NR 546, Advanced Psychopharmacology, provides a rigorous and
comprehensive review of essential concepts required for the final examination. It encompasses the full spectrum of
psychopharmacological agents, including antidepressants, antipsychotics, mood stabilizers, anxiolytics, stimulants,
and cognitive enhancers, with emphasis on mechanisms of action, indications, side effects, and monitoring
parameters. Special attention is given to vulnerable populations, such as children, elderly, and pregnant women,
as well as the management of substance use disorders. The content is grounded in the latest evidence-based
guidelines and incorporates clinical decision-making frameworks to enhance critical thinking. Each of the 150
questions is designed to test higher-order knowledge, with detailed rationales that explain both correct and
Page 1
,incorrect options. This resource is an invaluable tool for nursing students seeking to achieve a top grade and to
apply psychopharmacological principles safely in clinical practice.
Keywords:
NR 546, Psychopharmacology, Advanced Pharmacology, Exam Prep, Nursing, Mental Health, Drug Interactions,
Clinical Guidelines
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale explaining why it is correct, along
with explanations for why the other options are incorrect. Rationales include clinical pearls, mechanism of action,
side effect profiles, and relevant guidelines to reinforce learning.
Compliance Checklist:
All answers verified against current evidence-based sources
Content aligned with 2026-2027 NR 546 curriculum and exam blueprint
Questions reflect the latest FDA approvals and safety warnings
Rationales are detailed and reference clinical practice guidelines
Suitable for self-assessment and final exam review
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of 1-15 Neurotransmission, receptor pharmacology, 10%
Psychopharmacology pharmacokinetics, pharmacodynamics
Antidepressants 16-35 SSRIs, SNRIs, TCAs, MAOIs, atypical 13%
antidepressants, treatment-resistant
depression
Antipsychotics 36-55 First-generation, second-generation, side 13%
effects, metabolic monitoring
Mood Stabilizers 56-70 Lithium, valproate, lamotrigine, 10%
carbamazepine, monitoring
Anxiolytics and 71-85 Benzodiazepines, buspirone, Z-drugs, 10%
Sedative-Hypnotics withdrawal management
Stimulants and ADHD 86-100 Methylphenidate, amphetamines, 10%
Medications atomoxetine, alpha-2 agonists,
cardiovascular monitoring
Cognitive Enhancers 101-110 Donepezil, rivastigmine, galantamine, 7%
memantine, dementia management
Substance Use Disorder 111-125 Nicotine replacement, naltrexone, 10%
Pharmacotherapy buprenorphine, methadone, acamprosate,
disulfiram
Special Populations 126-135 Pediatric, geriatric, pregnancy, lactation, 7%
renal/hepatic impairment
Clinical Integration and Case 136-150 Drug interactions, patient education, 10%
Studies adherence, legal/ethical issues, case-based
application
Page 2
,Q1. A patient with treatment-resistant depression is currently on fluoxetine 60 mg
daily. The provider considers augmenting with a second agent. Which of the following
combinations is most likely to precipitate serotonin syndrome due to a
pharmacodynamic interaction?
A. Adding bupropion
B. Adding mirtazapine
C. Adding lithium
D. Adding buspirone
Correct Answer: B. Adding mirtazapine
Rationale: Mirtazapine, though a noradrenergic and specific serotonergic antidepressant,
enhances serotonergic transmission through 5-HT2 and 5-HT3 antagonism and alpha-2
antagonism, which can increase serotonin levels when combined with an SSRI, raising the
risk of serotonin syndrome. Bupropion primarily affects dopamine and norepinephrine,
lithium has minimal serotonergic effects, and buspirone is a partial 5-HT1A agonist with a
safer profile in this context.
Why Wrong:
A - Bupropion does not significantly increase serotonin and is a common
augmentation strategy with lower serotonin syndrome risk.
C - Lithium has minimal serotonergic effects and is a standard augmentation, though
it may rarely contribute to serotonin syndrome.
D - Buspirone is a partial 5-HT1A agonist and is generally considered safer in
combination with SSRIs.
Reference: Stahl, S. M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 3
Q2. A 30-year-old patient with schizophrenia has been stabilized on clozapine for 6
months. A routine complete blood count reveals an absolute neutrophil count (ANC)
of 1,200/mm³. According to the FDA's Risk Evaluation and Mitigation Strategy
(REMS) for clozapine, what is the required immediate action?
A. Continue clozapine with twice-weekly ANC monitoring
B. Interrupt clozapine treatment and monitor ANC daily until 1,500/mm³
C. Continue clozapine but increase monitoring to weekly
D. Discontinue clozapine permanently and consider alternative antipsychotic
Correct Answer: B. Interrupt clozapine treatment and monitor ANC daily until
1,500/mm³
Rationale: Per the clozapine REMS, an ANC between 1,000 and 1,499/mm³ is classified
as moderate neutropenia, requiring interruption of treatment and daily ANC monitoring
until the ANC is 1,500/mm³. This allows for potential rechallenge once the ANC recovers,
whereas permanent discontinuation is reserved for severe neutropenia (ANC <500/mm³)
or other high-risk scenarios.
Page 3
, Why Wrong:
A - This would be appropriate for mild neutropenia (ANC 1,500-2,000/mm³) with
weekly monitoring, not for this level.
C - Weekly monitoring is not sufficient for moderate neutropenia; daily monitoring is
required after interruption.
D - Permanent discontinuation is not required for moderate neutropenia; rechallenge is
possible after recovery.
Reference: Clozapine REMS Program. (2024). Prescriber Information.
Q3. Which of the following best describes the primary mechanism by which valproate
exerts its mood-stabilizing effects in bipolar disorder?
A. Enhancement of GABAergic transmission through inhibition of GABA
transaminase
B. Blockade of voltage-gated sodium channels leading to reduced glutamate release
C. Inhibition of histone deacetylase resulting in altered gene expression
D. Antagonism of dopamine D2 receptors in the mesolimbic pathway
Correct Answer: A. Enhancement of GABAergic transmission through inhibition of
GABA transaminase
Rationale: Valproate increases GABA concentrations by inhibiting GABA transaminase
and succinic semialdehyde dehydrogenase, thereby enhancing inhibitory
neurotransmission. While it also blocks sodium channels and inhibits HDAC, the
GABAergic enhancement is considered a primary mechanism for its mood-stabilizing and
anticonvulsant effects. D2 antagonism is more characteristic of antipsychotics.
Why Wrong:
B - Sodium channel blockade contributes to its anticonvulsant effect but is not the
primary mood-stabilizing mechanism.
C - HDAC inhibition is a novel mechanism but not the primary established action for
mood stabilization.
D - Valproate does not significantly antagonize D2 receptors.
Reference: Brunton, L. L., et al. (2023). Goodman & Gilman's The Pharmacological Basis
of Therapeutics, 14th Ed., Ch. 17
Q4. A patient with generalized anxiety disorder and a history of substance use
disorder is started on a medication that requires gradual titration due to initial
worsening of anxiety. Which agent is being described, and what is the rationale for
the titration?
A. Buspirone: delayed onset of full anxiolytic effect requires 2-4 weeks
B. Gabapentin: dose-dependent sedation necessitates slow upward titration
C. Escitalopram: initial serotonergic overactivity can exacerbate anxiety before
downregulation
Page 4
Verified Questions - 129 Questions with Answers
NR 546 Final Exam 2026-129 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation resource for NR 546, Advanced Psychopharmacology, offers
150 meticulously verified questions and answers, all graded A+. Designed for the 2026/2027 academic
year, it aligns with the latest guidelines and evidence-based practices. Each question is accompanied by
detailed rationales to reinforce understanding and ensure exam readiness. This document is an essential
tool for nursing students aiming to excel in their final examination.
Key Features:
Foundations of Psychopharmacology: Neurotransmission, receptor pharmacology, and pharmacokinetics
Antidepressants: SSRIs, SNRIs, TCAs, MAOIs, and atypical antidepressants
Antipsychotics: First-generation (typical) and second-generation (atypical) agents
Mood Stabilizers: Lithium, valproate, lamotrigine, and other anticonvulsants
Anxiolytics and Sedative-Hypnotics: Benzodiazepines, buspirone, and non-benzodiazepine hypnotics
Stimulants and Non-Stimulants for ADHD: Methylphenidate, amphetamines, atomoxetine, and alpha-2
agonists
Cognitive Enhancers: Donepezil, rivastigmine, galantamine, and memantine for dementia
Substance Use Disorder Pharmacotherapy: Nicotine, alcohol, opioid, and other substance use treatments
Special Populations: Pediatric, geriatric, pregnancy, and lactation considerations
Psychopharmacology in Medical Conditions: Drug interactions, contraindications, and monitoring
Patient Education and Adherence: Strategies for improving medication adherence and patient counseling
Legal and Ethical Considerations: Prescriptive authority, informed consent, and controlled substance
regulations
Evidence-Based Practice: Clinical guidelines, algorithms, and outcome measures
Case-Based Application: Integrating psychopharmacology into clinical scenarios
Recent Advances: New drugs, research findings, and updates in the field
Exam Strategies: Test-taking tips and common pitfalls
Updates for 2026:
- Updated to reflect the latest FDA approvals and warnings in psychopharmacology
- Revised to align with 2026-2027 clinical practice guidelines from APA and other organizations
- Enhanced rationales to include evidence-based research and clinical pearls
- Expanded coverage of telepsychiatry and digital health considerations in medication management
- Incorporated new safety alerts and drug interaction data
Abstract:
This exam preparation document for NR 546, Advanced Psychopharmacology, provides a rigorous and
comprehensive review of essential concepts required for the final examination. It encompasses the full spectrum of
psychopharmacological agents, including antidepressants, antipsychotics, mood stabilizers, anxiolytics, stimulants,
and cognitive enhancers, with emphasis on mechanisms of action, indications, side effects, and monitoring
parameters. Special attention is given to vulnerable populations, such as children, elderly, and pregnant women,
as well as the management of substance use disorders. The content is grounded in the latest evidence-based
guidelines and incorporates clinical decision-making frameworks to enhance critical thinking. Each of the 150
questions is designed to test higher-order knowledge, with detailed rationales that explain both correct and
Page 1
,incorrect options. This resource is an invaluable tool for nursing students seeking to achieve a top grade and to
apply psychopharmacological principles safely in clinical practice.
Keywords:
NR 546, Psychopharmacology, Advanced Pharmacology, Exam Prep, Nursing, Mental Health, Drug Interactions,
Clinical Guidelines
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale explaining why it is correct, along
with explanations for why the other options are incorrect. Rationales include clinical pearls, mechanism of action,
side effect profiles, and relevant guidelines to reinforce learning.
Compliance Checklist:
All answers verified against current evidence-based sources
Content aligned with 2026-2027 NR 546 curriculum and exam blueprint
Questions reflect the latest FDA approvals and safety warnings
Rationales are detailed and reference clinical practice guidelines
Suitable for self-assessment and final exam review
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of 1-15 Neurotransmission, receptor pharmacology, 10%
Psychopharmacology pharmacokinetics, pharmacodynamics
Antidepressants 16-35 SSRIs, SNRIs, TCAs, MAOIs, atypical 13%
antidepressants, treatment-resistant
depression
Antipsychotics 36-55 First-generation, second-generation, side 13%
effects, metabolic monitoring
Mood Stabilizers 56-70 Lithium, valproate, lamotrigine, 10%
carbamazepine, monitoring
Anxiolytics and 71-85 Benzodiazepines, buspirone, Z-drugs, 10%
Sedative-Hypnotics withdrawal management
Stimulants and ADHD 86-100 Methylphenidate, amphetamines, 10%
Medications atomoxetine, alpha-2 agonists,
cardiovascular monitoring
Cognitive Enhancers 101-110 Donepezil, rivastigmine, galantamine, 7%
memantine, dementia management
Substance Use Disorder 111-125 Nicotine replacement, naltrexone, 10%
Pharmacotherapy buprenorphine, methadone, acamprosate,
disulfiram
Special Populations 126-135 Pediatric, geriatric, pregnancy, lactation, 7%
renal/hepatic impairment
Clinical Integration and Case 136-150 Drug interactions, patient education, 10%
Studies adherence, legal/ethical issues, case-based
application
Page 2
,Q1. A patient with treatment-resistant depression is currently on fluoxetine 60 mg
daily. The provider considers augmenting with a second agent. Which of the following
combinations is most likely to precipitate serotonin syndrome due to a
pharmacodynamic interaction?
A. Adding bupropion
B. Adding mirtazapine
C. Adding lithium
D. Adding buspirone
Correct Answer: B. Adding mirtazapine
Rationale: Mirtazapine, though a noradrenergic and specific serotonergic antidepressant,
enhances serotonergic transmission through 5-HT2 and 5-HT3 antagonism and alpha-2
antagonism, which can increase serotonin levels when combined with an SSRI, raising the
risk of serotonin syndrome. Bupropion primarily affects dopamine and norepinephrine,
lithium has minimal serotonergic effects, and buspirone is a partial 5-HT1A agonist with a
safer profile in this context.
Why Wrong:
A - Bupropion does not significantly increase serotonin and is a common
augmentation strategy with lower serotonin syndrome risk.
C - Lithium has minimal serotonergic effects and is a standard augmentation, though
it may rarely contribute to serotonin syndrome.
D - Buspirone is a partial 5-HT1A agonist and is generally considered safer in
combination with SSRIs.
Reference: Stahl, S. M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 3
Q2. A 30-year-old patient with schizophrenia has been stabilized on clozapine for 6
months. A routine complete blood count reveals an absolute neutrophil count (ANC)
of 1,200/mm³. According to the FDA's Risk Evaluation and Mitigation Strategy
(REMS) for clozapine, what is the required immediate action?
A. Continue clozapine with twice-weekly ANC monitoring
B. Interrupt clozapine treatment and monitor ANC daily until 1,500/mm³
C. Continue clozapine but increase monitoring to weekly
D. Discontinue clozapine permanently and consider alternative antipsychotic
Correct Answer: B. Interrupt clozapine treatment and monitor ANC daily until
1,500/mm³
Rationale: Per the clozapine REMS, an ANC between 1,000 and 1,499/mm³ is classified
as moderate neutropenia, requiring interruption of treatment and daily ANC monitoring
until the ANC is 1,500/mm³. This allows for potential rechallenge once the ANC recovers,
whereas permanent discontinuation is reserved for severe neutropenia (ANC <500/mm³)
or other high-risk scenarios.
Page 3
, Why Wrong:
A - This would be appropriate for mild neutropenia (ANC 1,500-2,000/mm³) with
weekly monitoring, not for this level.
C - Weekly monitoring is not sufficient for moderate neutropenia; daily monitoring is
required after interruption.
D - Permanent discontinuation is not required for moderate neutropenia; rechallenge is
possible after recovery.
Reference: Clozapine REMS Program. (2024). Prescriber Information.
Q3. Which of the following best describes the primary mechanism by which valproate
exerts its mood-stabilizing effects in bipolar disorder?
A. Enhancement of GABAergic transmission through inhibition of GABA
transaminase
B. Blockade of voltage-gated sodium channels leading to reduced glutamate release
C. Inhibition of histone deacetylase resulting in altered gene expression
D. Antagonism of dopamine D2 receptors in the mesolimbic pathway
Correct Answer: A. Enhancement of GABAergic transmission through inhibition of
GABA transaminase
Rationale: Valproate increases GABA concentrations by inhibiting GABA transaminase
and succinic semialdehyde dehydrogenase, thereby enhancing inhibitory
neurotransmission. While it also blocks sodium channels and inhibits HDAC, the
GABAergic enhancement is considered a primary mechanism for its mood-stabilizing and
anticonvulsant effects. D2 antagonism is more characteristic of antipsychotics.
Why Wrong:
B - Sodium channel blockade contributes to its anticonvulsant effect but is not the
primary mood-stabilizing mechanism.
C - HDAC inhibition is a novel mechanism but not the primary established action for
mood stabilization.
D - Valproate does not significantly antagonize D2 receptors.
Reference: Brunton, L. L., et al. (2023). Goodman & Gilman's The Pharmacological Basis
of Therapeutics, 14th Ed., Ch. 17
Q4. A patient with generalized anxiety disorder and a history of substance use
disorder is started on a medication that requires gradual titration due to initial
worsening of anxiety. Which agent is being described, and what is the rationale for
the titration?
A. Buspirone: delayed onset of full anxiolytic effect requires 2-4 weeks
B. Gabapentin: dose-dependent sedation necessitates slow upward titration
C. Escitalopram: initial serotonergic overactivity can exacerbate anxiety before
downregulation
Page 4
